Latest New England Journal Stories
Bariatric surgery reduces the long-term risk of developing diabetes by over 80 % among people with obesity.
In the medical world, where decisions invariably involve risk and uncertainty, two Beth Israel Deaconess Medical Center physicians note that experts generally base their recommendations on the outcome of death, which is "readily determined, easily quantified, concrete."
Although some studies have portrayed tight blood sugar control as a potential means of lowering infection rates in critically ill adults, a new study—led by principal investigator Michael Agus, MD, director of the Medicine Critical Care Program at Boston Children's Hospital—found no indication that the approach benefits pediatric patients undergoing heart surgery.
Each year, nearly 2 million people die from tuberculosis – a treatable disease that has been brought under control in the United States, but continues to ravage other parts of the world.
Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination carries a greater risk of gastrointestinal bleeding.
For patients with stable coronary artery disease who have at least one narrowed blood vessel that compromises flow to the heart, medical therapy alone leads to a significantly higher risk of hospitalization and the urgent need for a coronary stent when compared with therapy that also includes initial placement of artery-opening stents.
The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs – prasugrel and clopidogrel – in preventing the first occurrence of death, heart attack or stroke.
A clinical study led by National Institutes of Health investigators has identified an antibody that compromises the immune systems of HIV-negative people, making them susceptible to infections with opportunistic microbes such as nontuberculous mycobacteria (NTM).
An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis.